Companies: 10,795·Total market cap: $144.5T
RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZBNASDAQHealthcare
$62.49
+$0.01(+0.02%)
Market Cap$3.8B
P/E Ratio—
52W High$62.51
52W Low$17.95
EarningsFinancialsRevenue

RayzeBio, Inc. Common Stock (RYZB) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

RYZB · earnings · updated Jun 8, 2026

Latest Earnings

Q4 FY2023
EPS Actual
-$1.26
Est. -$0.69 · -82.6%
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 13, 2023
After Market Close
▼ Miss EPS
RYZB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—

EPS & Revenue vs. Estimates

Actual (Beat)
Actual (Miss)
Estimated

Earnings History

Q1 FY2024
Mar 4, 2024
EPS Actual
—
EPS Est.
-$0.38
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 13, 2023Miss
EPS Actual
-$1.26
EPS Est.
-$0.69
EPS Surpr.
-82.6%
Revenue
—
Q4 FY2022
Dec 31, 2022
EPS Actual
-$0.44
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Sep 30, 2022
EPS Actual
-$0.51
EPS Est.
—
EPS Surpr.
—
Revenue
—
No analyst estimates available for RYZB.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.
Q4 FY2023+1.53%
Report Date
Nov 13, 2023
EPS Beat/Miss
-82.6%
Price Before
$20.24
Price After
$20.55
Q4 FY2022—
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
—
Price After
$24.00
Q3 FY2022—
Report Date
Sep 30, 2022
EPS Beat/Miss
—
Price Before
—
Price After
$24.00
Avg Miss Reaction+1.53%
Beat Rate0 / 3 quarters
Largest Move+1.53% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Data source: Financial Modeling Prep (FMP)  |  Updated: Hourly  |  Surprise%: (Actual − Estimate) / |Estimate| × 100  |  Fiscal year: RYZB ends December

RayzeBio, Inc. Common Stock (RYZB) most recently reported earnings on November 13, 2023 for Q4 FY2023, posting EPS of $-1.26 — missing the analyst consensus of $-0.69 by -82.6%. The next RYZB earnings date is expected around September 1, 2026.

Each quarter, investors track RYZB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RYZB revenue tab →

Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RYZB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
RevenuePrice historyFinancial statementsForecastDividendsMarket cap

Frequently asked questions

RYZB earnings · 5 questions

RayzeBio, Inc. Common Stock's next earnings report is expected around September 1, 2026. RYZB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RYZB historically reports after market close (AMC).

RYZB earnings datewhen is RYZB earningsRYZB next earnings datewhen does RYZB report earningsRYZB earnings calendar

▸ Source: FMP · RayzeBio, Inc. Common Stock SEC filings · US GAAP · RayzeBio, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026